This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Grifols Announces Launch Of The SPIRIT Registry At The NHF Annual Meeting

RESEARCH TRIANGLE PARK, N.C., Oct. 4, 2013 /PRNewswire/ -- Grifols Inc., a leading manufacturer of life-saving plasma protein therapies, today announced the launch of the SPIRIT ( S tudy of P lasma-derived factor VIII/VWF in I mmune tole R ance I nduction T herapy) registry for patients with hemophilia A at the National Hemophilia Foundation (NHF) annual meeting in Anaheim, Calif. The SPIRIT registry will enroll U.S. patients with hemophilia A and inhibitors being treated with Grifols' plasma-derived factor VIII/VWF product, ALPHANATE ® (antihemophilic factor/von Willebrand factor complex [human]).

(Logo: )

According to the registry's lead investigator, Rebecca Kruse-Jarres, M.D., of Tulane University, this observational study fills an important void.

"There is not a lot of prospective data to help us understand how patients with inhibitors respond to treatment, especially as it relates to adherence and quality of life. The data from the SPIRIT registry will give us more information to treat our patients and should complement the ongoing RESIST study."

Dr. Kruse-Jarres will present a poster at the NHF meeting that outlines the registry design.

"The SPIRIT registry is another example of Grifols' commitment to the hemophilia community," said Eva Bastida, Ph.D., Vice President of Scientific and Medical Affairs at Grifols. "We are happy to launch this initiative and further support efforts to provide information to hemophilia treaters."


Indications ALPHANATE ® (antihemophilic factor/von Willebrand factor complex [human]) is indicated for:
  • Control and prevention of bleeding in patients with hemophilia A
  • Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery

Important Safety Information

ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs